Literature DB >> 19188772

Nerve-sparing focal cryoablation of prostate cancer.

Thomas J Polascik1, Janice M Mayes, Vladimir Mouraviev.   

Abstract

PURPOSE OF REVIEW: We evaluate the rationale, candidate selection, and results of the first clinical studies of focal cryoablation for select patients with low volume and low-to-low - moderate risk features of prostate cancer as a possible alternative to whole gland treatment. RECENT
FINDINGS: For a select cohort of patients with low-to-low - moderate risk unifocal or unilateral prostate cancer, a number of ablative treatment options for focal therapy are available with cryotherapy having the most clinical experience. However, retrospective pathological data from large prostatectomy series do not clearly reveal valid and reproducible criteria to select appropriate candidates for focal cryoablation due to the complexity of tumorigenesis in early stage disease.
SUMMARY: The concept of focal therapy is evolving with the understanding of the biologic variability (clinically aggressive, significant, or insignificant) of prostate cancers that may require different treatment approaches. Minimally-invasive, parenchyma-preserving cryoablation can be considered as a potential feasible option in the treatment armamentarium of early stage, localized prostate cancer in appropriately selected candidates.

Entities:  

Mesh:

Year:  2009        PMID: 19188772     DOI: 10.1097/MOU.0b013e328323f603

Source DB:  PubMed          Journal:  Curr Opin Urol        ISSN: 0963-0643            Impact factor:   2.309


  6 in total

1.  Hemiablation of Localized Prostate Cancer by High-Intensity Focused Ultrasound: A Series of 35 Cases.

Authors:  Peter V Glybochko; Alexander V Amosov; German E Krupinov; Nikolay V Petrovskii; Ilya S Lumpov
Journal:  Oncology       Date:  2019-05-09       Impact factor: 2.935

2.  Recent advances in focal therapy of prostate and kidney cancer.

Authors:  Matvey Tsivian; Thomas J Polascik
Journal:  F1000 Med Rep       Date:  2010-01-18

Review 3.  Pathologic basis of focal therapy for early-stage prostate cancer.

Authors:  Vladimir Mouraviev; Janice M Mayes; Thomas J Polascik
Journal:  Nat Rev Urol       Date:  2009-04       Impact factor: 14.432

4.  Parameters predicting postoperative unilateral disease in patients with unilateral prostate cancer in diagnostic biopsy: a rationale for selecting hemiablative focal therapy candidates.

Authors:  Stavros Sfoungaristos; Petros Perimenis
Journal:  Can Urol Assoc J       Date:  2013 Jan-Feb       Impact factor: 1.862

5.  Endorectal MRI and MR spectroscopic imaging of prostate cancer: developing selection criteria for MR-guided focal therapy.

Authors:  Stephanie T Chang; Antonio C Westphalen; Priyanka Jha; Adam J Jung; Peter R Carroll; John Kurhanewicz; Fergus V Coakley
Journal:  J Magn Reson Imaging       Date:  2013-05-16       Impact factor: 4.813

6.  Pros and cons of focal therapy for localised prostate cancer.

Authors:  Luigi Mearini; Massimo Porena
Journal:  Prostate Cancer       Date:  2011-05-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.